# Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

> **NCT00123487** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 638 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic, Accelerated Phase
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

## Interventions

- **DRUG:** dasatinib
- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00123487
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-11
- **Final completion:** 2013-06
- **Target enrollment:** 638 (ACTUAL)
- **Last updated:** 2014-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123487, "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00123487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*